Methanobrevibacter Smithii Test · Stool

If you deal with persistent constipation, bloating that arrives regardless of what you eat, or a digestive rhythm that feels stuck in slow motion, a single gut microbe may be part of the story. Methanobrevibacter smithii is the dominant methane-producing organism in the human gut, and its abundance has been repeatedly tied to how fast or slow your bowel moves, how much energy you pull from food, and how your gut communicates with the rest of your body.

This test counts how much of this specific microbe is living in your stool. The result does not give you a disease diagnosis, but it fills in a piece of the puzzle that a generic stool test, a routine metabolic panel, and even most breath tests do not directly report. It is one of the clearest windows into whether methane biology is shaping your digestion.

What This Microbe Actually Does In Your Gut

M. smithii (Methanobrevibacter smithii) is not a bacterium. It belongs to a separate branch of life called archaea. It is found in roughly 90 to 99 percent of healthy adults, and it starts colonizing you very early, with traces detected in the stomachs of one-day-old newborns and in colostrum and breast milk.

Its job is specialized. It consumes hydrogen gas produced by other gut microbes and combines it with carbon dioxide to make methane. By pulling hydrogen out of the mix, it changes the chemistry of your colon in ways that can influence how efficiently neighboring bacteria ferment fiber, how much short-chain fatty acid they produce, and how quickly stool moves through your intestine.

Why High Levels Are Linked to Constipation

The single clearest clinical signal tied to this microbe is a slow, constipated gut. In people with constipation-predominant irritable bowel syndrome (IBS-C), stool M. smithii counts are consistently higher than in healthy controls, and higher counts line up with more methane on a breath test and fewer bowel movements per week.

The methane itself appears to slow down intestinal contractions. In research using breath testing, a fasting methane reading of 10 parts per million or higher accurately identifies a condition called intestinal methanogen overgrowth (IMO) with sensitivity of about 86 percent and specificity of 100 percent compared with standard 2-hour breath testing. Stool M. smithii abundance tracks closely with that breath methane signal.

What this means for you: if you have sluggish stools, bloating, or an IBS diagnosis that has never been subtyped, a stool M. smithii level gives you a more concrete biological target than vague labels like "functional constipation."

Links to Body Weight and Metabolism

M. smithii sits at an interesting crossroads of energy balance. Studies comparing lean and obese adults generally find higher levels in lean people and lower levels in obesity, and in children with obesity a similar pattern shows up against metabolic blood markers. At the other extreme, people with anorexia nervosa show markedly elevated levels, which researchers interpret as a biological adaptation that may help pull more calories from a restricted diet.

One complication: in a childhood cohort of 472 kids, high stool colonization with this microbe at age two was linked to a higher risk of being overweight later in childhood. And a small trial in prediabetic adults with obesity showed that eradicating methane production with antibiotics, which also dropped stool M. smithii, was followed by better cholesterol, LDL, insulin, and glucose numbers.

This is not a "high is bad, low is good" marker. Very low levels are linked to obesity and severe malnutrition. Very high levels are linked to constipation, anorexia, and some childhood weight gain. The framework that makes both findings consistent is that M. smithii shapes how efficiently your gut extracts and slows down nutrient flow. The right amount depends on your body and your current metabolic state, which is why tracking the number over time and in context matters more than any single reading.

Inflammatory Bowel Disease and Other Gut Conditions

M. smithii levels tend to be lower in people with inflammatory bowel disease, including both Crohn disease and ulcerative colitis, and also in kidney transplant recipients, who show altered gut fermentation and reduced methane production. A lower level in these settings seems to reflect broader damage or disruption of the gut ecosystem rather than a protective trait.

In severe acute malnutrition in children, this microbe is almost absent, dropping from roughly 36 percent prevalence in healthy controls to around 4 percent in malnourished children. Researchers have proposed that loss of M. smithii is part of why undernourished children cannot recover normal gut function, rather than a consequence of slow maturation.

Links Beyond the Gut

In multiple sclerosis, stool levels of Methanobrevibacter are elevated and correlate with changes in immune signaling. A long-term-care study of 159 older adults found that people with severe cognitive impairment had more methane-producing microbes and less microbial capacity to make neuroprotective metabolites. A study of roughly 1,800 samples linked M. smithii to colorectal cancer, where it appears to support the growth of cancer-associated bacteria rather than cause the cancer directly.

These associations are real but early. They do not mean a high or low level predicts any of these diseases on its own. They do mean that your M. smithii level is a window into how your gut ecosystem is wired, and shifts in that wiring show up across many organ systems.

Reference Ranges Are Still Being Worked Out

There are no universally standardized clinical cutpoints for this microbe. Different labs use different assays, including stool quantitative PCR (a DNA-counting method) and shotgun sequencing, and the numbers they report are not directly interchangeable. The values below come from published research and are offered only as orientation.

Compare your own result within the same lab over time for the most meaningful trend. Do not treat any single number as a universal threshold.

Tracking Your Trend

A single stool sample captures a moment in your microbiome, not a permanent trait. Diet in the last few days, recent travel, antibiotic use, and even transit time can shift any stool microbial reading. Your trend over months tells you far more than any single number.

A practical cadence: get a baseline, retest in 3 to 6 months if you are actively changing diet, addressing constipation, or going through a course of targeted antibiotics for methane, and then at least annually. Stability or direction of change is what tells you whether an intervention is actually shifting the biology, not a one-time result.

What to Do If Your Level Is High or Low

A high stool M. smithii level alongside chronic constipation, bloating, or slow transit is the pattern most worth acting on. Pair it with a hydrogen and methane breath test to confirm that methane production is high, because stool abundance and breath output can sometimes diverge. A gastroenterologist who works with methane-predominant intestinal methanogen overgrowth is the right person to help interpret the combination and consider a trial of targeted therapy.

A very low or undetectable level has different implications. In an adult with inflammatory bowel disease, recent antibiotic use, or significant weight loss, a low level likely reflects broader gut disruption and should be considered alongside stool calprotectin, inflammation markers, and a review of recent medications. In a child with signs of undernutrition, an absent or extremely low level should prompt a workup for malnutrition and gut barrier issues rather than reassurance.

When Results Can Be Misleading

A single stool sample is sensitive to several things that can distort the picture:

• Recent antibiotics: a course of antibiotics in the prior weeks can temporarily suppress M. smithii without reflecting your usual gut state. Wait at least 4 weeks after finishing antibiotics before sampling.
• Acute diarrheal illness: a bout of gastroenteritis reshuffles stool microbial counts for days to weeks. Retest once your bowel pattern returns to your normal.
• Oral corticosteroid use: in a large gut microbiome study, systemic corticosteroid users had increased M. smithii. If you are on or recently off oral steroids, interpret a high level with that context in mind.
• Sample handling: archaea are oxygen-sensitive, and delays or temperature swings between collection and processing can affect the count. Follow your kit instructions precisely.